Comparing the Effectiveness of Three Oral Medications Used for Migraine Prevention

Project Summary

This study compares the clinical effectiveness of Atogepant to Topiramate and Propranolol among adults who have migraine.

Who will this research inform?

Migraine affects approximately 14% of the U.S. population. Results from this study will be informative to adults, clinicians, payers and policy makers as they consider ways to select amongst migraine preventive medication options and shorten the time required to find an effective and tolerable treatment for individuals with migraine.

What is the research team doing?

DesignRandomized controlled trialPopulation1,200 adults 18-70 years of age who have at least 4 migraine days per monthInterventions/ComparatorsAtogepant: 60mg, 1 time per day Topiramate: titrated up to 50mg, 2 times per dayPropranolol: titrated up to 80mg, 2 times per dayPrimary OutcomesTolerability of and response to treatment as measured by staying on the medication for 12 weeks and having a 50% or greater reduction in migraine day frequencySecondary OutcomesHeadache impact on functioning, medication related adverse events, quality of lifePatient and Community EngagementPatients, clinicians, scientists, health system representatives, payer organization representatives, pharmacists and leaders from professional organizations are working with researchers on this study.